Hager Biosciences, LLC

is a preclinical-stage organization specializing in innovative discovery medicinal chemistry. The company's mission is to become a preferred partner to pharmaceutical and biotech firms by providing through out-licensing for unmet medical needs. Key to their business model is the capability to design and synthesize proprietary small for modular adaptation into new or existing drug candidate optimization or novelization projects. Its discovery provides a competitive and efficient advantage for rapid novel lead generation, optimization, and drug rescue. Hager's highly cost-effective and efficient discovery research process, including using outsourced network infrastructures, has a solid track record of innovative preclinical pharmaceutical candidate discovery in , attested by several generated. Recent examples of awarded as well as filed from which two clinical candidates are on the verge of entering for include: 11,505,555 10,329,301 11,414,425 10,815,242 11,142,529 11,312,721 16/445,854 63/399,509 WO2020247447 WO2020247445 US2022/0259224 63/403,019 63/400,894